Clinical outcomes are complex and often involve multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of conjunctivitis treatment programs require individual development, typically including drug therapy, rehabilitation interventions, and regular follow-up multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of conjunctivitis. The platform serves the China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide patients with the following services: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by a team of experts; 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.